Jones Financial Companies
TRML

Jones Financial Companies’s Tourmaline Bio TRML Stock Holding History

Jones Financial Companies’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$1.67K – 4158
2025
Q1 		$1.67K Buy
+100
New +$1.6K ﹤0.01% 3291

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Jones Financial Companies's TRML Position: Q2 2025 in Review

Jones Financial Companies sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 100 shares — an estimated $1.67K sold.

Jones Financial Companies first reported a position in TRML in Q1 2025 and held it in 1 quarter. The position peaked at $1.67K in Q1 2025. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • Jones Financial Companies reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • Jones Financial Companies sold 100 Tourmaline Bio shares in Q2 2025, an estimated $1.67K.
  • Jones Financial Companies first reported a position in Tourmaline Bio in Q1 2025 and held it in 1 quarter.
  • Jones Financial Companies's Tourmaline Bio position peaked at $1.67K in Q1 2025.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Jones Financial Companies's 13F filing for Q2 2025, filed 13 Aug 2025.